MX2021014844A - Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva. - Google Patents
Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva.Info
- Publication number
- MX2021014844A MX2021014844A MX2021014844A MX2021014844A MX2021014844A MX 2021014844 A MX2021014844 A MX 2021014844A MX 2021014844 A MX2021014844 A MX 2021014844A MX 2021014844 A MX2021014844 A MX 2021014844A MX 2021014844 A MX2021014844 A MX 2021014844A
- Authority
- MX
- Mexico
- Prior art keywords
- cognitive function
- leucine
- acetyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 230000003920 cognitive function Effects 0.000 title abstract 3
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 title abstract 2
- 229960000669 acetylleucine Drugs 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 230000037230 mobility Effects 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente descripción está dirigida a acetil-leucina o una sal farmacéuticamente aceptable de la misma para usarse en la mejora de la función cognitiva, movilidad o función cognitiva y movilidad en un sujeto, por ejemplo, en un sujeto anciano.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201606834 | 2016-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014844A true MX2021014844A (es) | 2022-01-18 |
Family
ID=58633040
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012739A MX2018012739A (es) | 2016-04-19 | 2017-04-19 | Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva. |
| MX2021014844A MX2021014844A (es) | 2016-04-19 | 2018-10-18 | Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012739A MX2018012739A (es) | 2016-04-19 | 2017-04-19 | Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10905670B2 (es) |
| EP (1) | EP3445351A1 (es) |
| JP (2) | JP7387264B2 (es) |
| KR (4) | KR20180134398A (es) |
| CN (1) | CN109069463A (es) |
| AU (2) | AU2017252507B2 (es) |
| BR (1) | BR112018071547A2 (es) |
| CA (1) | CA3021155A1 (es) |
| IL (3) | IL262379B (es) |
| MX (2) | MX2018012739A (es) |
| RU (2) | RU2745912C2 (es) |
| SG (2) | SG10202106190RA (es) |
| WO (1) | WO2017182802A1 (es) |
| ZA (1) | ZA201806849B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7387264B2 (ja) * | 2016-04-19 | 2023-11-28 | イントラバイオ リミティド | 改善される運動性及び認知機能のためのアセチル－ロイシン又はその薬学的に許容される塩 |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| JP7471298B2 (ja) * | 2018-12-06 | 2024-04-19 | イントラビオ エルティーディー | アセチル－ロイシンの重水素化類似体 |
| CA3131948A1 (en) * | 2019-03-02 | 2020-09-10 | Intrabio Ltd. | Leucine, acetyl leucine, and related analogs for treating disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| US20120196257A1 (en) * | 2009-08-27 | 2012-08-02 | Joe Verghese | Cognitive function training to improve motor ability |
| TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| WO2012060844A1 (en) * | 2010-11-05 | 2012-05-10 | Biotie Therapies, Inc | A2a antagonists as cognition and motor function enhancers |
| JP7387264B2 (ja) * | 2016-04-19 | 2023-11-28 | イントラバイオ リミティド | 改善される運動性及び認知機能のためのアセチル－ロイシン又はその薬学的に許容される塩 |
| US20200338034A1 (en) * | 2017-10-18 | 2020-10-29 | Intrabio Ltd | Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders |
-
2017
- 2017-04-19 JP JP2018555644A patent/JP7387264B2/ja active Active
- 2017-04-19 BR BR112018071547-6A patent/BR112018071547A2/pt active Search and Examination
- 2017-04-19 CA CA3021155A patent/CA3021155A1/en active Pending
- 2017-04-19 IL IL262379A patent/IL262379B/en unknown
- 2017-04-19 CN CN201780029480.6A patent/CN109069463A/zh active Pending
- 2017-04-19 MX MX2018012739A patent/MX2018012739A/es unknown
- 2017-04-19 KR KR1020187032983A patent/KR20180134398A/ko not_active IP Right Cessation
- 2017-04-19 KR KR1020227008412A patent/KR102413754B1/ko active IP Right Grant
- 2017-04-19 EP EP17719692.0A patent/EP3445351A1/en active Pending
- 2017-04-19 RU RU2018140131A patent/RU2745912C2/ru active
- 2017-04-19 SG SG10202106190RA patent/SG10202106190RA/en unknown
- 2017-04-19 KR KR1020247003393A patent/KR20240018683A/ko active Application Filing
- 2017-04-19 KR KR1020227021015A patent/KR102632670B1/ko active IP Right Grant
- 2017-04-19 RU RU2021107001A patent/RU2021107001A/ru unknown
- 2017-04-19 US US16/093,780 patent/US10905670B2/en active Active
- 2017-04-19 WO PCT/GB2017/051090 patent/WO2017182802A1/en active Application Filing
- 2017-04-19 IL IL310508A patent/IL310508A/en unknown
- 2017-04-19 AU AU2017252507A patent/AU2017252507B2/en active Active
- 2017-04-19 SG SG11201809031XA patent/SG11201809031XA/en unknown
-
2018
- 2018-10-15 ZA ZA2018/06849A patent/ZA201806849B/en unknown
- 2018-10-18 MX MX2021014844A patent/MX2021014844A/es unknown
-
2020
- 2020-12-22 US US17/247,757 patent/US11998518B2/en active Active
-
2021
- 2021-11-12 JP JP2021185130A patent/JP7506046B2/ja active Active
-
2022
- 2022-05-23 IL IL293266A patent/IL293266B2/en unknown
- 2022-10-17 AU AU2022256077A patent/AU2022256077A1/en active Pending
-
2023
- 2023-07-10 US US18/349,221 patent/US20230346732A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019012534A (es) | Combinacion de elafibranor o derivados del mismo con un agente anti-ehna, antifibrotico o anticolestasico. | |
| NZ733055A (en) | Anti-c10orf54 antibodies and uses thereof | |
| PH12015502788A1 (en) | Antibody formulations and methods | |
| CA160630S (en) | Body groomer | |
| MX2021014844A (es) | Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva. | |
| MX2016004853A (es) | Metodos de uso de anticuerpos anti-ly6e. | |
| MX2021010886A (es) | Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson. | |
| SG10201907901XA (en) | Antibodies, uses & methods | |
| AU363883S (en) | Tracking device | |
| MX2018005785A (es) | Conjugados de anticuerpo anti-cd22-maytansina y metodos de uso de los mismos. | |
| SG11201912228WA (en) | Agents, uses and methods for treatment | |
| MX2017016096A (es) | Agente antihipertensivo. | |
| IL280191A (en) | Dissolved dosages, methods and use | |
| MX368268B (es) | Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih). | |
| SG11201912827TA (en) | 7-substituted pyrrolotriazine compounds or pharmaceutically acceptable salts thereof, and preparation methods and uses thereof | |
| MX2019014090A (es) | Métodos para el tratamiento de la reservoritis crónica. | |
| MX2019005504A (es) | Potenciadores de bmp. | |
| NZ747201A (en) | (+)-azasetron for use in the treatment of ear disorders | |
| SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
| IN2013MU02813A (es) | ||
| TWD176882S (zh) | 按摩裝置 | |
| MX2018002193A (es) | Metodo de uso de quinoxalinilo-piperazinamida. | |
| UA98069U (xx) | N-(3-ТРИФТОРМЕТИЛФЕНІЛ)-2-(2-ОКСО-3,5a,6,11b-ТЕТРАГІДРО-2Н,5Н-ХРОМЕНО[4',3':4,5]ТІОПІРАНО[2,3-d][1,3]ТІАЗОЛ-3-ІЛ)АЦЕТАМІД, ЩО ПРОЯВЛЯЄ АНАБОЛІЧНУ ТА АНДРОГЕННУ ДІЮ | |
| UA92247U (ru) | ПРИМЕНЕНИЕ МЕТИЛОВОГО ЭСТЕРА 5-МЕТИЛ-4-ОКСО-3,4-ДИГИДРОТИЕНО[2,3-d]ПИРИМИДИН-6-КАРБОНОВОЙ КИСЛОТЫ КАК АНАЛЬГЕТИЧЕСКОГО И ПРОТИВОВОСПАЛИТЕЛЬНОГО СРЕДСТВА | |
| TWD173312S (zh) | 下肢復健機側板之部分 |